Stack Financial Management Inc Has $34.56 Million Position in Zoetis Inc (NYSE:ZTS)

Stack Financial Management Inc lowered its holdings in shares of Zoetis Inc (NYSE:ZTS) by 3.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 304,558 shares of the company’s stock after selling 9,802 shares during the quarter. Zoetis accounts for about 3.9% of Stack Financial Management Inc’s portfolio, making the stock its 6th largest position. Stack Financial Management Inc owned about 0.06% of Zoetis worth $34,564,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ZTS. FMR LLC lifted its position in Zoetis by 12.2% during the first quarter. FMR LLC now owns 8,127,931 shares of the company’s stock valued at $818,239,000 after purchasing an additional 882,183 shares during the last quarter. BlackRock Inc. raised its stake in shares of Zoetis by 2.2% in the first quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock valued at $3,773,759,000 after acquiring an additional 795,558 shares during the period. Geode Capital Management LLC raised its stake in shares of Zoetis by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock valued at $531,801,000 after acquiring an additional 785,088 shares during the period. American Century Companies Inc. raised its stake in shares of Zoetis by 12.8% in the first quarter. American Century Companies Inc. now owns 4,539,546 shares of the company’s stock valued at $456,996,000 after acquiring an additional 513,924 shares during the period. Finally, Close Asset Management Ltd purchased a new stake in shares of Zoetis in the first quarter valued at $47,140,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

In other news, insider Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $113.09, for a total value of $692,450.07. Following the sale, the insider now directly owns 46,812 shares in the company, valued at approximately $5,293,969.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,900 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $110.58, for a total transaction of $210,102.00. Following the completion of the sale, the director now owns 2,816 shares in the company, valued at $311,393.28. The disclosure for this sale can be found here. Insiders have sold a total of 47,160 shares of company stock worth $4,969,469 in the last three months. Insiders own 0.29% of the company’s stock.

Several brokerages have recently weighed in on ZTS. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and increased their target price for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Craig Hallum increased their target price on shares of Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets increased their target price on shares of Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a research note on Thursday, May 9th. Guggenheim began coverage on shares of Zoetis in a research note on Thursday, May 23rd. They issued a “buy” rating and a $114.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 target price (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $113.13.

ZTS stock traded up $0.96 during trading on Friday, hitting $125.07. The company had a trading volume of 1,612,606 shares, compared to its average volume of 1,966,388. The stock has a market cap of $59.41 billion, a price-to-earnings ratio of 39.96, a P/E/G ratio of 3.14 and a beta of 0.92. Zoetis Inc has a 52-week low of $78.90 and a 52-week high of $125.88. The firm has a 50 day moving average of $115.02. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.79.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.77 EPS. As a group, analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be given a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 21.09%.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: How are capital gains distributions different for tax-deferred account?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.